Myosana Therapeutics Raises $5 Million in Seed Funding

SEATTLE–(BUSINESS WIRE)–Myosana Therapeutics, Inc., pioneer of a muscle-specific non-viral gene therapy platform for neuromuscular and cardiac diseases, today announced the completion of a seed funding round totaling over $5 million led by investor John Ballantyne, Ph.D. The capital will go toward developing Myosana’s platform with the goal of identifying the first development candidate for Duchenne muscular dystrophy by 2025. “Built on decades of expertise in neuromuscular diseases, Myosana’
Click here to view original post